Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma
The purpose is to evaluate the effectiveness and safety of Surufatinib in patients with osteosarcoma and soft tissue sarcoma after Standard chemotherapy therapy.
Sarcoma
DRUG: Surufatinib
Progression-free rate at 12weeks, at 12weeks
Progression-free survival (PFS), up to 12 months|Objective response rate (ORR), up to 12 months|Disease control rate (DCR), up to 12 months|Overall survival (OS), up to 24 months
The study population is patients with advanced osteosarcoma and soft tissue sarcoma who have failed in standard chemotherapy treatment. Surufatinib 300 mg once a day (QD) will be orally administrated on a 21-day cycle. Investigators will evaluate the clinical tumor response to Surufatinib, and if investigators determine that the patient can benefit from the continuation of treatment, the patient will continue the Surufatinib treatment. The duration of study will be 2 years. At the time of study completion, if investigators believe patients can continue to benefit from the investigational product, patients may be provided with Surufatinib with the agreement of the sponsor.